Choriocarcinoma

• CLINICAL_TRIALS research · 2026-02-24
  Clinical Trial Update: A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT [Phase 2]

  This is a Phase 2 clinical trial evaluating a new treatment approach for central nervous system nongerminomatous germ cell tumors in childre…

• CLINICAL_TRIALS research · 2025-10-24
  Clinical Trial Update: Molecular Epidemiology of Pediatric Germ Cell Tumors

  A pediatric clinical trial by the Children's Oncology Group to study the molecular epidemiology of germ cell tumors and their histologic sub…

• CLINICAL_TRIALS research · 2025-08-11
  Clinical Trial Update: Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia [NA]

  A clinical trial evaluating biweekly Actinomycin-D versus multi-day Methotrexate for low-risk gestational trophoblastic neoplasia; status is…

• CLINICAL_TRIALS trial_result · 2025-01-13
  Clinical Trial Update: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors [Phase 3]

  This entry describes a Phase 3 trial comparing standard-dose versus high-dose combination chemotherapy with stem cell transplant for relapse…

• FDA approval · 2024-10-23
  FDA Approved: JYLAMVO — Supplemental Application (SHORLA ONCOLOGY INC.)

  The FDA approved a supplemental application for JYLAMVO (methotrexate) filed by SHORLA ONCOLOGY INC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2024-06-03
  FDA Approved: METHOTREXATE — Original Application (Alembic Pharmaceuticals Inc.)

  FDA approved Alembic Pharmaceuticals' original application for methotrexate, authorizing the generic version of the drug.

• FDA approval · 2022-11-29
  FDA Approved: JYLAMVO — Original Application (SHORLA ONCOLOGY INC.)

  FDA approved JYLAMVO (methotrexate) under an Original Application from SHORLA ONCOLOGY INC.

• FDA approval · 2021-10-25
  FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc. (ANDA089342).

• FDA approval · 2021-10-25
  FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  FDA approves a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc., enabling a new generic version of the drug.

• FDA approval · 2021-06-14
  FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)

  The FDA approved a supplemental application for TREXALL (methotrexate) filed by Teva Women's Health, Inc.

• FDA approval · 2020-01-30
  FDA Approved: METHOTREXATE — Original Application (Chartwell RX, LLC)

  FDA approvedChartwell RX, LLC's methotrexate product under an Original Application, making a new generic version of methotrexate available. …

• CLINICAL_TRIALS trial_result · 2019-08-13
  Clinical Trial Update: Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia [Phase 3]

  Phase 3 trial evaluating dactinomycin or methotrexate for low-risk gestational trophoblastic neoplasia has completed with results posted.

• CLINICAL_TRIALS trial_result · 2019-06-11
  Clinical Trial Update: TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma [Phase 2]

  Phase 2 trial evaluating TRC105 with standard-dose bevacizumab in two patients with metastatic and refractory choriocarcinoma has completed;…

• CLINICAL_TRIALS trial_result · 2019-06-04
  Clinical Trial Update: Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) [Phase 2]

  Phase 2 trial of TRC105 with bevacizumab in refractory gestational trophoblastic neoplasia terminated; results posted in 2019.

• FDA approval · 2018-03-15
  FDA Approved: METHOTREXATE — Supplemental Application (Hospira, Inc.)

  FDA approved a supplemental application for Methotrexate submitted by Hospira, Inc.

• FDA approval · 2016-12-20
  FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)

  FDA approved a supplemental application for TREXALL (methotrexate) from Teva Women's Health, Inc.

• FDA approval · 2013-02-05
  FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved Hikma Pharmaceuticals USA's supplemental application for methotrexate, enabling the marketing of a generic methotrexate product…

• FDA approval · 2011-04-25
  FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  The FDA approved a supplemental application for METHOTREXATE from Hikma Pharmaceuticals USA Inc., granting a supplemental approval for the g…

• CLINICAL_TRIALS trial_result · 2007-08-09
  Clinical Trial Update: A Trial for Patients With Gestational Trophoblastic Disease [Phase 2]

  Phase 2 trial update for gestational trophoblastic disease reports completion of the study with conditions including trophoblastic neoplasms…

• FDA approval · 2007-04-30
  FDA Approved: METHOTREXATE — Original Application (Accord Healthcare, Inc.)

  The FDA approved Accord Healthcare's original application for Methotrexate (generic).